| The heterogeneity of prostate cancer: a practical approach Y Tolkach, G Kristiansen Pathobiology 85 (1-2), 108-116, 2018 | 111 | 2018 |
| High-accuracy prostate cancer pathology using deep learning Y Tolkach, T Dohmgörgen, M Toma, G Kristiansen Nature Machine Intelligence 2 (7), 411-418, 2020 | 88 | 2020 |
| Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma FG Heinemann, Y Tolkach, M Deng, D Schmidt, S Perner, G Kristiansen, ... Clinical epigenetics 10, 1-9, 2018 | 80 | 2018 |
| Comprehensive evaluation of prostate specific membrane antigen expression in the vasculature of renal tumors: implications for imaging studies and prognostic role S Spatz, Y Tolkach, K Jung, C Stephan, J Busch, B Ralla, A Rabien, ... The Journal of urology 199 (2), 370-377, 2018 | 75 | 2018 |
| Quality control stress test for deep learning-based diagnostic model in digital pathology B Schömig-Markiefka, A Pryalukhin, W Hulla, A Bychkov, J Fukuoka, ... Modern Pathology 34 (12), 2098-2108, 2021 | 59 | 2021 |
| The N6‐methyladenosine (m6A) erasers alkylation repair homologue 5 (ALKBH5) and fat mass and obesity‐associated protein (FTO) are prognostic biomarkers … A Strick, F von Hagen, L Gundert, N Klümper, Y Tolkach, D Schmidt, ... BJU international 125 (4), 617-624, 2020 | 49 | 2020 |
| PITX2 DNA methylation as biomarker for individualized risk assessment of prostate cancer in core biopsies B Uhl, H Gevensleben, Y Tolkach, V Sailer, M Majores, M Jung, S Meller, ... The Journal of Molecular Diagnostics 19 (1), 107-114, 2017 | 46 | 2017 |
| Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy Y Tolkach, H Gevensleben, R Bundschuh, A Koyun, D Huber, C Kehrer, ... Breast cancer research and treatment 169, 447-455, 2018 | 45 | 2018 |
| Systematic analysis of the expression of the mitochondrial ATP synthase (complex V) subunits in clear cell renal cell carcinoma M Brüggemann, A Gromes, M Poss, D Schmidt, N Klümper, Y Tolkach, ... Translational oncology 10 (4), 661-668, 2017 | 45 | 2017 |
| 5′-tRNA halves are dysregulated in clear cell renal cell carcinoma C Zhao, Y Tolkach, D Schmidt, G Kristiansen, SC Müller, J Ellinger The Journal of urology 199 (2), 378-383, 2018 | 44 | 2018 |
| P athogenic and targetable genetic alterations in 70 urachal adenocarcinomas H Reis, KE van der Vos, C Niedworok, T Herold, O Módos, A Szendrői, ... International Journal of Cancer 143 (7), 1764-1773, 2018 | 41 | 2018 |
| Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy X Chen, C Bernemann, Y Tolkach, M Heller, C Nientiedt, M Falkenstein, ... Urologic Oncology: Seminars and Original Investigations 36 (4), 161. e19-161 …, 2018 | 37 | 2018 |
| Sensitivity of HOXB13 as a diagnostic immunohistochemical marker of prostatic origin in prostate cancer metastases: comparison to PSA, prostein, androgen receptor, ERG, NKX3. 1 … I Kristiansen, C Stephan, K Jung, M Dietel, A Rieger, Y Tolkach, ... International journal of molecular sciences 18 (6), 1151, 2017 | 36 | 2017 |
| Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imaging Y Tolkach, D Goltz, A Kremer, H Ahmadzadehfar, D Bergheim, M Essler, ... Oncotarget 10 (41), 4149, 2019 | 34 | 2019 |
| Initial experiences with the Hemopatch® as a hemostatic agent in zero-ischemia partial nephrectomy F Imkamp, Y Tolkach, M Wolters, S Jutzi, M Kramer, T Herrmann World journal of urology 33, 1527-1534, 2015 | 34 | 2015 |
| Luteinizing hormone‐releasing hormone (LHRH) receptor agonists vs antagonists: a matter of the receptors? Y Tolkach, S Joniau, H Van Poppel BJU international 111 (7), 1021-1030, 2013 | 29 | 2013 |
| Apelin and apelin receptor expression in renal cell carcinoma Y Tolkach, J Ellinger, A Kremer, L Esser, SC Müller, C Stephan, K Jung, ... British journal of cancer 120 (6), 633-639, 2019 | 28 | 2019 |
| Three‐dimensional reconstruction of prostate cancer architecture with serial immunohistochemical sections: hallmarks of tumour growth, tumour compartmentalisation, and … Y Tolkach, S Thomann, G Kristiansen Histopathology 72 (6), 1051-1059, 2018 | 28 | 2018 |
| Systematic expression analysis of the mitochondrial complex III subunits identifies UQCRC1 as biomarker in clear cell renal cell carcinoma J Ellinger, A Gromes, M Poss, M Brüggemann, D Schmidt, N Ellinger, ... Oncotarget 7 (52), 86490, 2016 | 26 | 2016 |
| tRNA-halves are prognostic biomarkers for patients with prostate cancer C Zhao, Y Tolkach, D Schmidt, M Muders, G Kristiansen, SC Müller, ... Urologic Oncology: Seminars and Original Investigations 36 (11), 503. e1-503. e7, 2018 | 24 | 2018 |
Glen KristiansenProfessor für Pathologie在 ukb.uni-bonn.de 的电子邮件经过验证
